|

Osimertinib plus Dalpiciclib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1

Indications

  • Cell Cycle Deregulation1
  • EGFR Activating Mutation1
  • EGFR-TKI Resistant Mutation1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1

Other1 trial

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.